Sucralfate + Metronidazole + Lignocaine Cream

Sucralfate + Metronidazole + Lignocaine Cream belongs to the Creams and External Preparations category, positioned within the Gastroenterology and Dermatology therapeutic segments. This prescription anorectal cream addresses three simultaneous physiological challenges in anorectal wound management — mucosal integrity, microbiological protection, and pain control — that cannot be adequately managed by single-agent topical therapy.

Sucralfate IP 7% w/w is the primary wound-healing agent: a polyanionic aluminium salt that polymerizes on damaged mucosal surfaces to form a cytoprotective gel barrier. Metronidazole IP 1% w/w provides targeted antimicrobial coverage against anaerobic bacteria and protozoa — the primary microbiological threats in the anorectal wound environment. Lignocaine Hydrochloride IP 4% w/w delivers rapid and reliable local anaesthesia, reducing the severe pain and reflex internal sphincter spasm that complicates anal fissure and post-operative anorectal recovery.

Saar Biotech manufactures this formulation at our Baddi manufacturing facility for B2B third-party and contract manufacturing partners across India, in 20gm and 30gm laminated tube formats with applicator options.

At Saar Biotech, we manufacture Sucralfate + Metronidazole + Lignocaine Cream using a precision-controlled three-API semi-solid homogenization process that ensures complete uniform dispersion and chemical compatibility of all three active ingredients.

• Sucralfate Dispersion Stability: Sucralfate at 7% concentration must remain homogeneously suspended in the cream base without particle settling or cream phase separation. Our validated blending sequence uses controlled-speed mixing at defined temperature ranges to maintain dispersion uniformity across the full batch volume.
• Metronidazole Chemical Stability: Metronidazole requires a pH-stable environment to prevent nitro-group reduction and degradation. Our cream base pH is engineered to maintain metronidazole within its optimal stability window while remaining compatible with the sucralfate suspension system.
• Lignocaine Potency Maintenance: At 4% concentration, lignocaine HCl is a high-potency anaesthetic component that requires tight assay control. Our final HPLC batch release protocol independently confirms lignocaine content against IP reference standards before batch authorization.
• Applicator-Ready Tube Design: Our 20gm and 30gm tubes are designed with nozzle geometry compatible with rectal applicator attachment, allowing brands to include a disposable applicator in the carton for internal anorectal application indications.

Sucralfate + Metronidazole + Lignocaine Cream is manufactured by Saar Biotech for the following prescription-approved clinical applications:

• Chronic Anal Fissure: First-line prescription topical for fissure healing — sucralfate promotes mucosal repair, lignocaine relieves sphincter spasm, metronidazole protects the wound
• Post-Haemorrhoidectomy Wound Care: Topical support for pain management, tissue protection, and microbiological control during post-surgical healing
• Pruritus Ani with Secondary Infection Risk: Perianal pruritus complicated by excoriation and anaerobic bacterial colonization of the wound surface
• Anorectal Wound Management: Broader prescription application in perianal skin conditions requiring concurrent barrier protection, antimicrobial coverage, and anaesthetic relief

Schedule H — Requires a valid medical prescription. Multi-active anorectal preparations must be used strictly under physician supervision for the prescribed duration.

Clinical Mechanism of Action

Sucralfate (7%) — in the acidic wound microenvironment (pH < 4), sucralfate undergoes dissociation and re-polymerization to form a large, viscous aluminium-sucrose-octasulphate polymer complex. This complex adheres selectively to ulcerated and denuded mucosal surfaces — binding protein-rich exudate — to form a protective physical barrier lasting 4–6 hours per application. Concurrently, sucralfate stimulates local prostaglandin E2 and I2 synthesis and epidermal growth factor secretion, both of which accelerate mucosal re-epithelialization.

Metronidazole (1%) — following cellular uptake by anaerobic organisms, metronidazole undergoes enzymatic reduction by ferredoxin-type electron transport proteins to generate reactive nitro-radical anions. These free radical intermediates interact with and strand-break microbial DNA, causing irreparable genetic damage and organism death. The molecule is selectively toxic to anaerobes because aerobic cells lack the reducing environment required for drug activation.

Lignocaine HCl (4%) — reversibly blocks fast-inactivating voltage-gated Na⁺ channels in the depolarized state, preventing the propagation of pain signals from anorectal sensory fibres to the CNS.

Manufacturing Integrity

• Three-API Compatibility: Full pre-formulation compatibility study confirms no chemical interaction between sucralfate’s polyanionic structure, metronidazole’s nitroimidazole ring, and lignocaine’s amide structure in the selected cream base.
• In-Process Sampling: Blending uniformity is confirmed by in-process sampling at three points (top, middle, bottom) of the mixing vessel before tube filling is authorized.

Saar Biotech provides Third-Party Manufacturing and Contract Manufacturing for Sucralfate + Metronidazole + Lignocaine Cream from our semi-solid manufacturing facility in Baddi, Himachal Pradesh.

• Facility: Semi-solid cream manufacturing block with jacketed planetary homogenizer mixing vessels, controlled temperature blending, automated laminated tube filling, sealing, and carton packing.
• Packaging: 20gm and 30gm laminated tubes — with carton, applicator insert, shrink pack, drip-off embossed carton options.
• MOQ: 5,000 to 2,00,000+ tubes per batch.
• Turnaround: New orders — 30–45 working days; Repeat orders — 20–25 working days.
• Documentation: COA, batch manufacturing record, stability data available on request.

Every commercial batch is released only after passing the following analytical protocol:

• Lignocaine HCl Assay (HPLC): Individual quantification against IP reference standard — acceptance 95–105% of label claim
• Metronidazole Assay (HPLC): Individual quantification against IP reference standard — acceptance 95–105% of label claim
• Sucralfate Identity & Assay: Per IP specification for sucralfate topical preparations
• pH Testing: Within approved cream base pH specification
• Viscosity Testing: Batch-to-batch consistency confirmation
• Microbial Limit Testing: Absence of specified pathogens; total aerobic count per IP topical standard
• Net Content per Tube: Within ±3% of declared fill weight
• Certificate of Analysis (COA): Provided with every B2B consignment

For B2B manufacturing enquiries, contract pricing, or complete product dossier for Sucralfate + Metronidazole + Lignocaine HCl Cream, please use the enquiry form below.